Skip to main content

Table 2 Baseline patient demographics and clinical characteristics

From: Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

 

H

N = 25

Median age (range)

55.0 (38–75)

Indication, n (%)

 Breast cancer

19 (76.0)

 Gastric cancer

6 (24.0)

Sex, n (%)

 Female

20 (80.0)

 Male

5 (20.0)

Country, n (%)

 Australia

1 (4.0)

 Belgium

1 (4.0)

 China

2 (8.0)

 Germany

4 (16.0)

 Hungary

1 (4.0)

 Israel

2 (8.0)

 Panama

1 (4.0)

 Poland

2 (8.0)

 Portugal

1 (4.0)

 Republic of Korea

6 (24.0)

 Russia

4 (16.0)

  1. Abbreviation: H trastuzumab (Herceptin®)